Literature DB >> 20634195

Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders.

Xianjin Zhou1, Zhiguo Nie, Amanda Roberts, Dongxian Zhang, Jonathan Sebat, Dheeraj Malhotra, John R Kelsoe, Mark A Geyer.   

Abstract

The reduced expression of the Sp4 gene in Sp4 hypomorphic mice resulted in subtle vacuolization in the hippocampus as well as deficits in sensorimotor gating and contextual memory, putative endophenotypes for schizophrenia and other psychiatric disorders. In this study, we examined both spatial learning/memory and hippocampal long-term potentiation (LTP) of Sp4 hypomorphic mice. Impaired spatial learning/memory and markedly reduced LTP were found. To corroborate the functional studies, the expression of N-methyl-D-aspartate (NMDA) glutamate receptors was investigated with both western blot and immunohistochemical analyses. The reduced expression of the Sp4 gene decreased the level of the NR1 subunit of NMDA receptors in Sp4 hypomorphic mice. In human, SP4 gene was found to be deleted sporadically in schizophrenia patients, corroborating evidence that polymorphisms of human SP4 gene are associated with schizophrenia and other psychiatric disorders. Impaired NMDA neurotransmission has been implicated in several human psychiatric disorders. As yet, it remains unclear how mutations of candidate susceptibility genes for these disorders may contribute to the disruption of NMDA neurotransmission. Sp4 hypomorphic mice could therefore serve as a genetic model to investigate impaired NMDA functions resulting from loss-of-function mutations of human SP4 gene in schizophrenia and/or other psychiatric disorders. Furthermore, aberrant expression of additional genes, besides NMDAR1, likely also contributes to the behavioral abnormalities in Sp4 hypomorphic mice. Thus, further investigation of the Sp4 pathway may provide novel insights in our understanding of a variety of neuropsychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634195      PMCID: PMC2935857          DOI: 10.1093/hmg/ddq298

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  45 in total

1.  Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

Authors:  A K Malhotra; D A Pinals; C M Adler; I Elman; A Clifton; D Pickar; A Breier
Journal:  Neuropsychopharmacology       Date:  1997-09       Impact factor: 7.853

2.  Schizophrenia and affective disorders--cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family.

Authors:  D H Blackwood; A Fordyce; M T Walker; D M St Clair; D J Porteous; W J Muir
Journal:  Am J Hum Genet       Date:  2001-07-06       Impact factor: 11.025

Review 3.  Assembly and forward trafficking of NMDA receptors (Review).

Authors:  F Anne Stephenson; Sarah L Cousins; Anna V Kenny
Journal:  Mol Membr Biol       Date:  2008-05       Impact factor: 2.857

4.  Genomic structure and localisation within a linkage hotspot of Disrupted In Schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia.

Authors:  J K Millar; S Christie; S Anderson; D Lawson; D Hsiao-Wei Loh; R S Devon; B Arveiler; W J Muir; D H Blackwood; D J Porteous
Journal:  Mol Psychiatry       Date:  2001-03       Impact factor: 15.992

Review 5.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

6.  Rare chromosomal deletions and duplications increase risk of schizophrenia.

Authors: 
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

7.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia.

Authors:  A C Lahti; H H Holcomb; D R Medoff; C A Tamminga
Journal:  Neuroreport       Date:  1995-04-19       Impact factor: 1.837

8.  Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine.

Authors:  V P Bakshi; M A Geyer
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

9.  Episodic memory performance predicted by the 2bp deletion in exon 6 of the "alpha 7-like" nicotinic receptor subunit gene.

Authors:  Emma L Dempster; Timothea Toulopoulou; Colm McDonald; Elvira Bramon; Muriel Walshe; Harvey Wickham; Pak C Sham; Robin M Murray; David A Collier
Journal:  Am J Psychiatry       Date:  2006-10       Impact factor: 18.112

10.  Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies.

Authors:  S I Shyn; J Shi; J B Kraft; J B Potash; J A Knowles; M M Weissman; H A Garriock; J S Yokoyama; P J McGrath; E J Peters; W A Scheftner; W Coryell; W B Lawson; D Jancic; P V Gejman; A R Sanders; P Holmans; S L Slager; D F Levinson; S P Hamilton
Journal:  Mol Psychiatry       Date:  2009-12-29       Impact factor: 15.992

View more
  21 in total

1.  GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders.

Authors:  Jared W Young; Mary E Kamenski; Kerin K Higa; Gregory A Light; Mark A Geyer; Xianjin Zhou
Journal:  Neuropsychopharmacology       Date:  2015-04-24       Impact factor: 7.853

2.  The transcription factor SP4 is reduced in postmortem cerebellum of bipolar disorder subjects: control by depolarization and lithium.

Authors:  Raquel Pinacho; Nuria Villalmanzo; Jasmin Lalonde; Josep Maria Haro; J Javier Meana; Grace Gill; Belén Ramos
Journal:  Bipolar Disord       Date:  2011 Aug-Sep       Impact factor: 6.744

3.  Transcription factor SP4 phosphorylation is altered in the postmortem cerebellum of bipolar disorder and schizophrenia subjects.

Authors:  Raquel Pinacho; Gregory Saia; J Javier Meana; Grace Gill; Belén Ramos
Journal:  Eur Neuropsychopharmacol       Date:  2015-05-21       Impact factor: 4.600

Review 4.  Mechanisms regulating dendritic arbor patterning.

Authors:  Fernanda Ledda; Gustavo Paratcha
Journal:  Cell Mol Life Sci       Date:  2017-07-22       Impact factor: 9.261

Review 5.  Preclinical Models to Investigate Mechanisms of Negative Symptoms in Schizophrenia.

Authors:  Samuel A Barnes; Andre Der-Avakian; Jared W Young
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

Review 6.  Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.

Authors:  Colm M P O'Tuathaigh; Paula M Moran; Xuechu C Zhen; John L Waddington
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

7.  Specificity protein 4 (Sp4) transcriptionally regulates inhibitory GABAergic receptors in neurons.

Authors:  Bindu Nair; Kaid Johar; Anusha Priya; Margaret T T Wong-Riley
Journal:  Biochim Biophys Acta       Date:  2015-10-18

8.  Transcription factor Sp4 regulates expression of nervous wreck 2 to control NMDAR1 levels and dendrite patterning.

Authors:  Xinxin Sun; Raquel Pinacho; Gregory Saia; Diana Punko; J Javier Meana; Belén Ramos; Grace Gill
Journal:  Dev Neurobiol       Date:  2014-07-22       Impact factor: 3.964

9.  Regulation of Na(+)/K(+)-ATPase by neuron-specific transcription factor Sp4: implication in the tight coupling of energy production, neuronal activity and energy consumption in neurons.

Authors:  Kaid Johar; Anusha Priya; Margaret T T Wong-Riley
Journal:  Eur J Neurosci       Date:  2013-11-12       Impact factor: 3.386

10.  Store-operated calcium entry promotes the degradation of the transcription factor Sp4 in resting neurons.

Authors:  Jasmin Lalonde; Gregory Saia; Grace Gill
Journal:  Sci Signal       Date:  2014-06-03       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.